◎ Sugi Atlas

Atlas / Drug / Etoposide

Etoposide

drug
On this page

Also known as Etoposide resolution mixtureEtoposidoEtoposidumNSC-141540SintopozidToposarVepesidVP-16EtopsideSID56463308Etoposide (VP-16)SID164339423EtoposidegC0164599

Summary

Etoposide (CHEMBL44657) is an approved small-molecule antineoplastic agent (ATC L01CB01) targeting TOP2A; indicated across 147 conditions including small cell lung carcinoma and neoplasm; with CIViC clinical evidence for 10 variant-indication associations (e.g. TP53 Overexpression in stomach cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01CB01
  • Targets: 1 (TOP2A)
  • Indications: 147 conditions
  • Clinical trials: 1,300
  • Precision-oncology evidence (CIViC): 10 variant–indication associations
  • Chemistry: 588.6 Da · C29H32O13

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL44657
NameEtoposide
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID36462
ChEBICHEBI:4911
ATCL01CB01
Molecular formulaC29H32O13
Molecular weight588.6
InChIKeyVJJPUSNTGOMMGY-MRVIYFEKSA-N

SMILES: C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

IUPAC name: (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one

Pharmacological roles (ChEBI): antineoplastic agent, DNA synthesis inhibitor.

Also known as: Etoposide, Etoposide resolution mixture, Etoposido, Etoposidum, NSC-141540, Sintopozid, Toposar, Vepesid, VP-16, etoposide, Etopside, ETOPOSIDE

Patent coverage: 57,548 distinct patent families (226,069 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 226,046 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TOP2ADNA topoisomerase II alphaInhibition7.399.6% (common-essential)P11388

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Nuclear receptor coactivator 3, Nuclear receptor coactivator 1, Solute carrier organic anion transporter family member 1B3, Latent membrane protein 1, DNA topoisomerase 2-alpha, DNA topoisomerase II, DNA topoisomerase 2-beta, Polyunsaturated fatty acid lipoxygenase ALOX15.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 38 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
TOP2B7.16IC5069.8nMCHEMBL_ACT_18438702
NCOA36.43IC50374.7nMCHEMBL_ACT_8260754
P032306.4AC50400nMCHEMBL_ACT_7471832
P032306.28AC50531nMCHEMBL_ACT_7362764
TOP2B6.1IC50790nMCHEMBL_ACT_18548571
TOP2A6.09EC50810nMCHEMBL_ACT_1139762
TOP2A6.09EC50810nMCHEMBL_ACT_1228466
TOP2A6.09EC50810nMCHEMBL_ACT_171992
TOP2A6.09EC50810nMCHEMBL_ACT_222775
TOP2A6.09EC50810nMCHEMBL_ACT_363954
NCOA15.94IC501153nMCHEMBL_ACT_9632427
P125305.5IC503187nMCHEMBL_ACT_7675964
SLCO1B35.38IC504180nMCHEMBL_ACT_15188475
TOP2A5.33IC504700nMCHEMBL_ACT_25558596

Target pathways

Aggregated over 1 target gene(s): TOP2A.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
Transcription of E2F targets under negative control by DREAM complex1TOP2A
SUMOylation of DNA replication proteins1TOP2A

Dominant GO biological processes

GO termTargets
resolution of meiotic recombination intermediates1
sister chromatid segregation1
hematopoietic progenitor cell differentiation1
DNA topological change1
chromatin organization1
DNA damage response1
chromosome segregation1
female meiotic nuclear division1
apoptotic chromosome condensation1
embryonic cleavage1
regulation of circadian rhythm1
positive regulation of apoptotic process1
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate1
positive regulation of transcription by RNA polymerase II1
rhythmic process1

Indications & clinical

Indications

147 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
small cell lung carcinoma4MONDO:0008433EFO:0000702
neoplasm4MONDO:0005070EFO:0000616
lung neoplasm4MONDO:0021117MONDO:0008903
small cell carcinoma4MONDO:0000402EFO:0008524
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
leukemia3MONDO:0005059EFO:0000565
neuroblastoma3MONDO:0005072EFO:0000621
ependymoma3MONDO:0016698EFO:1000028
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
medulloblastoma3MONDO:0007959EFO:0002939
mantle cell lymphoma3MONDO:0018876EFO:1001469
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
Ewing sarcoma3MONDO:0012817EFO:0000174
Hodgkins lymphoma3MONDO:0004952EFO:0000183
myelodysplastic syndrome3MONDO:0018881EFO:0000198
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
acute monocytic leukemia3MONDO:0007896EFO:0000221
acute myeloid leukemia3MONDO:0018874EFO:0000222
acute myelomonocytic leukemia M43MONDO:0018871EFO:0000223
Burkitt lymphoma3MONDO:0007243EFO:0000309
carcinoma3MONDO:0004993EFO:0000313
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
germ cell tumor3MONDO:0005040EFO:0000514
lymphoma3MONDO:0005062EFO:0000574
osteosarcoma3MONDO:0009807EFO:0000637
sarcoma3MONDO:0005089EFO:0000691
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
plasma cell myeloma3MONDO:0009693EFO:0001378
thymus neoplasm3MONDO:0005197EFO:0002626
rhabdomyosarcoma3MONDO:0005212EFO:0002918
acute megakaryoblastic leukemia3MONDO:0018872EFO:0003025
acute myeloblastic leukemia without maturation3MONDO:0005224EFO:0003027
acute basophilic leukemia3MONDO:0019458EFO:0003029
myelodysplastic syndrome with single lineage dysplasia3MONDO:0005272EFO:0003802
brain neoplasm3MONDO:0021211EFO:0003833
testicular cancer3MONDO:0005447EFO:0004281
lymphoid leukemia3MONDO:0005402EFO:0004289
primitive neuroectodermal tumor3MONDO:0005462EFO:0005235
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
myeloid sarcoma3MONDO:0006861EFO:1001052
soft tissue sarcoma3MONDO:0018078EFO:1001968
lung adenocarcinoma3MONDO:0005061EFO:0000571
adrenal cortex carcinoma3MONDO:0006639EFO:1000796
acute erythroid leukemia3MONDO:0017858EFO:0000218
ganglioneuroblastoma3MONDO:0005035EFO:0000502
myeloproliferative neoplasm3MONDO:0020076EFO:0002428
acute myeloblastic leukemia with maturation3MONDO:0020320EFO:0003028
myelodysplastic syndrome with excess blasts3MONDO:0019454EFO:0003811
mediastinal cancer3MONDO:0005843EFO:0007362
central nervous system neoplasm3MONDO:0006130EFO:1000158
hepatoblastoma3MONDO:0018666EFO:1000292
ovarian embryonal carcinoma3MONDO:0003581EFO:1000415
ovarian yolk sac tumor3MONDO:0006344EFO:1000437
choriocarcinoma of testis3MONDO:0003508EFO:1000564
testicular yolk sac tumor3MONDO:0003402EFO:1000574
chronic myelomonocytic leukemia3MONDO:0020311EFO:1001779
gastric neoplasm3MONDO:0021085MONDO:0001056
brain cancer3MONDO:0001657MONDO:0001657
kidney cancer3MONDO:0002367MONDO:0002367
teratoma3MONDO:0002601MONDO:0002601
seminoma3MONDO:0003001MONDO:0003001
breast neoplasm3MONDO:0021100MONDO:0007254
ovarian cancer3MONDO:0008170MONDO:0008170
follicular lymphoma3MONDO:0018906MONDO:0018906
Wilms tumor3MONDO:0006058MONDO:0019004
nasal cavity and paranasal sinus lethal midline granuloma3MONDO:0006828MONDO:0019472
HIV infectious disease3MONDO:0005109EFO:0000180
retinoblastoma3MONDO:0008380MONDO:0008380
B-cell acute lymphoblastic leukemia3MONDO:0004947EFO:0000094
colorectal neoplasm3MONDO:0005335MONDO:0005575
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
hepatocellular carcinoma2MONDO:0007256EFO:0000182
alveolar rhabdomyosarcoma2MONDO:0009994EFO:0000248
embryonal rhabdomyosarcoma2MONDO:0009993EFO:0000437
oligoastrocytoma2MONDO:0016702EFO:0000630
oligodendroglioma2MONDO:0016695EFO:0000632
anaplastic astrocytoma2MONDO:0016684EFO:0002499
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
relapsing-remitting multiple sclerosis2MONDO:0005314EFO:0003929
thymoma2MONDO:0006456EFO:1000581
gliosarcoma2MONDO:0016681EFO:1001465
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
hematologic disorder2MONDO:0005570HP:0001871
AIDS2MONDO:0012268EFO:0000765
stiff-person syndrome2MONDO:0008491EFO:0007498
optic nerve glioma2MONDO:0003235EFO:0009254
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
anaplastic oligodendroglioma2MONDO:0016696EFO:0002501
neuromyelitis optica2MONDO:0019100EFO:0004256
myasthenia gravis2MONDO:0009688EFO:0004991
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
Guillain-Barre syndrome, familial2MONDO:0007691EFO:0009538
opsoclonus-myoclonus syndrome2MONDO:0015247EFO:1001383
neutropenia2MONDO:0001475MONDO:0001475
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
graft versus host disease2MONDO:0013730MONDO:0013730
Castleman disease2MONDO:0015564MONDO:0015564
T-cell non-Hodgkin lymphoma2MONDO:0015760MONDO:0015760
astrocytoma (excluding glioblastoma)2MONDO:0019781MONDO:0016691
oropharynx cancer2MONDO:0004608MONDO:0021364
carcinoid tumor2MONDO:0005369MONDO:0024503
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
glioblastoma2MONDO:0018177EFO:0000519
MALT lymphoma2MONDO:0007650EFO:0000191
plasma cell neoplasm2MONDO:0004959EFO:0000200
prostate adenocarcinoma2MONDO:0005082EFO:0000673
lymphoid neoplasm2MONDO:0005157EFO:0001642
lung large cell carcinoma2MONDO:0003050EFO:0003050
olfactory neuroblastoma2MONDO:0006329EFO:1000407
paraganglioma2MONDO:0000448EFO:1000453
glioma2MONDO:0021042MONDO:0003268
chronic myeloid leukemia1MONDO:0011996EFO:0000339
Kaposi’s sarcoma1MONDO:0005055EFO:0000558
plasma cell leukemia1MONDO:0018689EFO:0006475
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
myelodysplastic/myeloproliferative disease1MONDO:0020077MONDO:0020077
primary effusion lymphoma1MONDO:0018842EFO:1000491
neuroendocrine neoplasm1MONDO:0019496EFO:1001901
neuroepithelial neoplasm0MONDO:0021193MONDO:0021193

24 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,300.

Phase distribution

PhaseTrials
PHASE2615
PHASE3277
PHASE1175
PHASE1/PHASE2127
Not specified48
PHASE2/PHASE327
PHASE418
EARLY_PHASE113

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05518383PHASE4RECRUITINGB-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT06931145PHASE4NOT_YET_RECRUITINGBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT00198991PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199147PHASE4UNKNOWNEfficacy of G-CSF-Priming in Elderly AML Patients
NCT00526175PHASE4COMPLETEDLAL-BR/2001: Study Treatment to Low Risk ALL
NCT01424839PHASE4UNKNOWNProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
NCT01501136PHASE4UNKNOWNTreatment of Natural Killer/T Cell Lymphoma-I/II
NCT01746992PHASE4UNKNOWNCTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
NCT01873807PHASE4UNKNOWNHD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL
NCT02036489PHASE4COMPLETEDPethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT02348450PHASE4UNKNOWNIrinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
NCT02858804PHASE4COMPLETEDEDOCH Alternating With DHAP for New Diagnosed Younger MCL
NCT03071822PHASE4UNKNOWNCombination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
NCT03707847PHASE4UNKNOWNCrizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
NCT04038411PHASE4UNKNOWNPD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
NCT04490590PHASE4UNKNOWNA Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
NCT04999878PHASE4UNKNOWNA Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
NCT05491304PHASE4UNKNOWNCytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
NCT00379340PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms’ Tumor
NCT00470223PHASE3ACTIVE_NOT_RECRUITINGCombined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00572169PHASE3ACTIVE_NOT_RECRUITINGUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT01704716PHASE3RECRUITINGHigh Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT02003222PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02101853PHASE3ACTIVE_NOT_RECRUITINGBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02112916PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02166463PHASE3ACTIVE_NOT_RECRUITINGBrentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02176967PHASE3ACTIVE_NOT_RECRUITINGResponse and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02306161PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02405676PHASE2/PHASE3ACTIVE_NOT_RECRUITINGBNHL-2015 for Children or Adolescents in China
NCT02429687PHASE3RECRUITINGTC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
NCT02429700PHASE3RECRUITINGTC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
NCT02443077PHASE3ACTIVE_NOT_RECRUITINGIbrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02521493PHASE3ACTIVE_NOT_RECRUITINGResponse-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02582697PHASE3RECRUITINGAccelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02661503PHASE3ACTIVE_NOT_RECRUITINGHD21 for Advanced Stages
NCT02845882PHASE3ACTIVE_NOT_RECRUITINGLBL-2016 for Children or Adolescents in China
NCT03007147PHASE3ACTIVE_NOT_RECRUITINGImatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03017326PHASE3ACTIVE_NOT_RECRUITINGPaediatric Hepatic International Tumour Trial
NCT03020030PHASE3ACTIVE_NOT_RECRUITINGTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03043872PHASE3ACTIVE_NOT_RECRUITINGDurvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Clinical evidence (CIViC)

Variant × indication × effect (10 predictive associations from 10 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
TP53 OverexpressionStomach CancerSensitivity/ResponseCisplatin + Mitomycin + EtoposideCIViC BEID2799
ETV6::NTRK3 FusionB-lymphoblastic Leukemia/lymphomaSensitivity/ResponseEtoposide + Methotrexate + LarotrectinibCIViC CEID8917
TP53 MutationStomach CarcinomaSensitivity/ResponseCisplatin + Etoposide + DoxorubicinCIViC CEID2820
TP53 R273CStomach CarcinomaSensitivity/ResponseEtoposide + Mitomycin + CisplatinCIViC CEID2292
TP53 Y220CStomach CarcinomaSensitivity/ResponseMitomycin + Cisplatin + EtoposideCIViC CEID2306
SF3B1 K700ELeukemiaSensitivity/ResponseEtoposide + OlaparibCIViC DEID10139
TOP2A TOP2A/90LeukemiaResistanceEtoposideCIViC DEID9634
TOP2A TOP2A/90LeukemiaResistanceEtoposide + Pixantrone + DVP Regimen + 4’-(9-acridinylamino)methanesulfon-m-anisidide + MVT RegimenCIViC DEID9635
TP53 R248QOvarian CancerResistancePaclitaxel + Doxorubicin + EtoposideCIViC DEID7175
NPM1 W288FSAcute Myeloid LeukemiaSensitivity/ResponseDaunorubicin + Cytarabine + EtoposideCIViC EEID153

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 16 clinical and 38 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

MoleculeSourceStatusShared targets
AMSACRINEChEMBLPhase 4 (approved)TOP2A
CIPROFLOXACINChEMBLPhase 4 (approved)TOP2A
DAUNORUBICINChEMBLPhase 4 (approved)TOP2A
DEXRAZOXANEChEMBLPhase 4 (approved)TOP2A
DOXORUBICINChEMBLPhase 4 (approved)TOP2A
EPIRUBICINChEMBLPhase 4 (approved)TOP2A
IDARUBICINChEMBLPhase 4 (approved)TOP2A
MITOXANTRONEChEMBLPhase 4 (approved)TOP2A
TENIPOSIDEChEMBLPhase 4 (approved)TOP2A
TOPOTECANChEMBLPhase 4 (approved)TOP2A
CURCUMINChEMBLPhase 3TOP2A
GEPOTIDACINChEMBLPhase 3TOP2A
AXL-1717ChEMBLPhase 2TOP2A
DECERNOTINIBChEMBLPhase 2TOP2A
LOSOXANTRONEChEMBLPhase 2TOP2A
NEMORUBICINChEMBLPhase 2TOP2A
PIROXANTRONEChEMBLPhase 2TOP2A
AfatinibPubChemApprovedTOP2A
BinimetinibPubChemApprovedTOP2A
CrizotinibPubChemApprovedTOP2A
GefitinibPubChemApprovedTOP2A
IdelalisibPubChemApprovedTOP2A
PazopanibPubChemApprovedTOP2A
podofiloxPubChemApprovedTOP2A
regorafenibPubChemApprovedTOP2A
SelumetinibPubChemApprovedTOP2A
TrametinibPubChemApprovedTOP2A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot